The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: A retrospective study

Cancer

Volumn 115, Issue 22, 2009, Pages 5132-5138

  Yang, Yu ^a   Qingbo, Lang ^a   Zhe, Chen ^a   Bai, Li ^a   Chaoqin, Yu ^a   Dezeng, Zhu ^a   Xiaofeng, Zhai ^a   Changquan, Ling ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Combination therapy; Hepatocellular carcinoma; Traditional Chinese herbal medicine; Transcatheter arterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; CISPLATIN; EPIRUBICIN; IODINATED POPPYSEED OIL; JDF; UNCLASSIFIED DRUG;

ACTINIDIA VALVATA; ADULT; AGED; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHICKEN; CHINESE MEDICINE; CONTROLLED STUDY; CREMASTRA APPENDICULATA; DIARRHEA; FEMALE; HERBAL MEDICINE; HUMAN; KIWIFRUIT; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; NOTE; PRIORITY JOURNAL; PROGNOSIS; SALVIA; SALVIA CHINENSIS;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 70449393540     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24567     Document Type: Note

References (28)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, Ga: American Cancer Society; 2007.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48:S20-S37.
3. Poon RTP, Fan ST, Tsang FHF, et al. Locoregional therapy for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002;235:466-486. (Pubitemid 34258345)
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
5. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734-1739. (Pubitemid 34607087)
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442. (Pubitemid 36152543)
7. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796-802. (Pubitemid 39030937)
8. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 2000;32:1224-1229.
9. Seong J, Park HC, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys. 2000;47:1331-1335. (Pubitemid 30421186)
10. Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ. Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata. Planta Med. 2004;70:171-173. (Pubitemid 38299781)
11. Xin HL, Yue XQ, Xu YF, et al. Two new polyoxgenated triterpenoids from actinidia valvata. Helvetica Chima Acta. 2008;91:575-580.
12. Liver Cancer Panel of the Chinese Anti-Cancer Association. The criteria for clinical diagnosis of primary liver cancer. Chin J Hepatol. 2001;9:324.
13. Greene FL, Page DL, Fleming ID, et al. eds. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia, Pa: Springer; 2002.
14. Tang ZY, ed. Tang Zhao-you's Hepatocellular Carcinoma: Clinical. Shanghai, China: Shanghai Scientific and Technological Education Publishing House; 2001:162.
15. Marelli L, Stigliano R, Triantos C. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594-606. (Pubitemid 44645026)
16. Buscarini L, Buscarini E, Di Stasi M, et al. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999;20:47-53. (Pubitemid 29215291)
17. Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89:1245-1251. (Pubitemid 30707442)
18. Yamakado K, Nakatsuka A, Akeboshi M, et al. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival. Oncol Rep. 2004;11:105-109.
19. Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable nonearly hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661-669. (Pubitemid 44149378)
20. Koda M, Murawaki Y, Mitsuda A. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer. 2001;92:1516-1524. (Pubitemid 32947837)
21. Bartolozzi C, Lencioni R, Caramella D. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197:812-818.
22. Akamatsu M, Yoshida H, Obi S. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int. 2004;24:625-629. (Pubitemid 40028616)
23. Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology. 1995;195:747-752.
24. Group d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256-1261.
25. Savastano S, Miotto D, Casarrubea G, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334-340. (Pubitemid 29246409)
26. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469. (Pubitemid 44142456)
27. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171. (Pubitemid 34454013)
28. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32:233-238. (Pubitemid 30614655)